Drug Trial Radar · NCT03714672
Tramadol/Diclofenac Fixed-dose Combination Phase III Trial in Acute Pain After Third Molar Extraction
Last checked: Nov 19, 2026Latest source record: Jul 24, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,151
Actual
Start
Aug 26, 2017
Primary completion
Mar 9, 2018
Study completion Mar 22, 2018
Sponsor
- Lead sponsor
- Grünenthal GmbHIndustry
- Sponsor type
- Industry
- Collaborators
- Grünenthal, S.A.
- First posted
- Oct 22, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluated a new drug fixed-dose combination tablet (FDC) called tramadol/diclofenac at two different strengths (fixed doses of 25 milligrams \[mg\] of tramadol and of diclofenac or of 50 mg each). Tramadol and diclofenac each relieve pain, but they do so by different mechanisms. They were used alone as comparator drug in this study. Both are marketed drugs and are standard treatment for acute pain, including wisdom tooth removal.
Conditions
- Acute Pain
Interventions
Tramadol/Diclofenac 50/50Drug
Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.
Tramadol/Diclofenac 25/25Drug
Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.
Tramadol 50Drug
Each dose comprised 1 capsule containing 50 mg tramadol hydrochloride and 3 placebo tablets matching the other active treatment groups. Doses were taken 8 hours apart.
Diclofenac 50Drug
Each dose comprised 1 tablet containing 50 mg diclofenac sodium and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pain Relief Expressed as Total Pain Relief (TOTPAR) Over the 4 Hours Post-dose Period (TOTPAR4)Time frame: Up to 4 hours after first dose
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Private Clinic
Aguascalientes, Mexico
Private Clinic
Chihuahua City, Mexico
Private Clinic
León, Mexico
Private Clinic
Puebla City, Mexico
University
San Luis Potosí City, Mexico
Private Clinic
Zapopan, Jalisco, Mexico
Private Clinic
Monterrey, Nuevo León, Mexico
Private Clinic
Monterrey, Nuevo León, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.